Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00463
2015-07-06
Prospective
KC/KE-15-0070/FR-2
Hong Kong Medical Supplies Ltd (Thea Laboratories)
Hong Kong Medical Supplies Ltd (Thea Laboratories)
N/A
Miss Mak Hoi Ching Haley
3/F, Hong Kong Eye Hospital, 147K, Argyle Street, Kowloon, Hong Kong
39435833
haleymak@cuhk.edu.hk
Department of Ophthalmology and Visual Sciences, Chinese University of Hong Kong
Dr. Vanissa Wing-see CHOW
3/F, Hong Kong Eye Hospital, 147K, Argyle Street, Mongkok, Kowloon, Hong Kong
39435833
vanissa.chow@gmail.com
Department of Ophthalmology, Hong Kong Eye Hospital
Azithromycin and Doxycycline in the Management of Meibomian Gland Dysfunction
Azithromycin and Doxycycline in the Management of Meibomian Gland Dysfunction
阿奇黴素 (Azithromycin) 和多西環素 (Doxycycline) 治療瞼板腺功能失調 (Meibomian gland dysfunction)
MGD
Hong Kong
Yes
2015-06-10
Azithromycin, doxycyline, MGD, blepharitis, dry eyes
Drug
Azithromycin 1.5% Topical; Doxycyline 100mg Oral; Multivitamin Daily 1 Plus 1 tablet Oral
Three months
- Group 1 (control treatment): topical azithromycin to both eyes, twice daily for 3 days, then once daily for 25 days; and oral multivitamin (Daily 1 Plus) 1 tablet a day concurrently for 28 days as placebo
- Group 2 (study treatment): topical azithromycin as above, and oral doxycycline 100mg (1 tablet) a day concurrently for 28 days.
- Symptomatic meibomian gland dysfunction not responding to warm compresses, lid massage, and lubricants
- Older than 12 year old
- Able to give informed consent
- Able to comply with treatment and follow-up schedule
- On treatment for MGD or dry eye syndrome other than warm compresses, lid massage and lubricants in the past 3 months
- Schirmer’s test without anaesthesia <5mm per 5 minutes in both eyes
- Pretreatment LipiView score ≥ 100 in both eyes
- Known allergy to tetracycline or macrolide
- Pregnant or breast feeding women
- Women planning pregnancy
- Hepatic impairment or on hepatotoxic drugs
- Severe renal impairment
- Ocular condition that causes similar symptoms and signs as MGD, including structural lid abnormalities, lagothalmos, conjunctivochalasis, contact lens wear, thyroid eye disease
- On systemic medications that may contribute to dry eye without being on a stable dose in the past 1 month
12
999
Both Male and Female
Interventional
Randomized
Active
Double-blind
Parallel
2015-07-18
50
Not Yet Recruiting
- Improvement in symptom frequency score based on self-administered OSDI questionnaire at month 1
- Improvement in symptom frequency score based on self-administered OSDI questionnaire at month 3
- Improvement in symptom severity score based on self-administered SPEED questionnaire
- Clinical grading of MGD based on conjunctival injection, lid margin redness, ocular surface staining, meibomian gland expressability, number of glands plugged and quality of meibum13
- Best- corrected visual acuity
- Lipid layer thickness measurement by LipiView interferometer (TearScience Inc., Morrisville, NC, USA)
The LipiView interferometer (TearScience Inc., Morrisville, NC, USA) measures interferometric color units (ICU), where 1 ICU approximately reflects 1 nm of the lipid layer thickness.18 A LipiView image of the tear film can be captured during a non-invasive in-office exam that takes about 5 minutes. The tear film can be seen as an array of colors called specular observations that are relected when the subject rest his head on the chin-rest and a controlled light source is directed towards the front surface of the eye.
- Non-invasive tear break-up time, infrared meibography, tear film assessment and R-scan (bulbar conjunctival redness evaluation) with OCULUS Keratograph 5M (Oculus, Wetzlar, Germany)
OCULUS Keratograph 5M (Oculus, Wetzlar, Germany) uses white or infrared illumination to assess the tear film and tear break-up time; infrared camera for meibomian gland imaging; and color camera for conjunctival blood vessel imaging. All measurements will be non-invasive. Subjects will be instructed to rest his head on the chin- rest during imaging, which takes about 5 minutes.
- Tear analysis (10 patients in each arm): osmolarity, cytokines, matrix metalloproteinases
- Side effects noted during treatment
- Compliance to treatment
2016-04-05
ChiCTR-IPC-15006715
Yes
N/A
|
|
|
|
|
---|---|---|---|---|
No documents yet. |